As expected, our study found that OXA activates the PI3K/AKT signaling pathway, promoting the proteasomal degradation of p53 in both primary and acquired resistance xenografts, thereby exacerbating OXA resistance in CRC cells. The gene discussed is TP53; the disease is colorectal carcinoma.